Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%(arstechnica.com)
136 points by _Microft | 25 comments
Ars Technica article reporting Phase 3 results showing Moderna and Merck's personalized mRNA melanoma vaccine with Keytruda cut recurrence or death risk by 42%.
















































![Screenshot of cambridge.org: ADHD, autism or complex trauma? [pdf]](https://hn.urlbox.com/shots/renders/2026/10/3/fb33af9b-2b23-4151-a0f2-092710be35bf.jpg)





































